Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

NCT04836156 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Early Breast Cancer

Interventions

DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
DRUG: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer

Sponsor

Peking University People's Hospital